Home > About Us

PDVI will work with public and private partners to accelerate the development and introduction of a dengue vaccine that is safe, effective and affordable for children in endemic countries.   OBJECTIVES OF STRATEGIC PARTNERSHIP • Establish and maintain the portfolio of private sector partnerships required to accelerate evaluation and introduction of dengue vaccines in developing countries, including the development and evaluation of diagnostic tests • Establish and maintain a spectrum of public sector partnerships required to accelerate evaluation and introduction of dengue vaccines in developing countries   OBJECTIVES OF SUPPORTIVE R&D • Improve dengue diagnostics through standardization of PRNT, validation of dengue diagnostic tests for current and past infection, and development of a test(s) for early, rapid diagnosis. • Develop an improved antibody test to define protection against dengue infection. • Develop an antibody test to predict risk of ADE.   OBJECTIVES OF VACCINE EVALUATION • Establishment of field sites for evaluation of dengue vaccines to determine their efficacy, effectiveness, and safety. • Development of clinical trial guidelines to assess vaccine efficacy, effectiveness, and safety. • Development of provisional dengue vaccination strategies for dengue endemic and non-endemic countries   OBJECTIVES OF VACCINE ACCESS • Conduct and evaluate health economic studies to make robust national, regional and international estimates of the cost of illness; the estimated cost effectiveness of dengue prevention through vaccination, including comparisons of different vaccination strategies and vector control programs; the estimated cost-effectiveness of dengue prevention compared to potential treatment with antiviral drugs; the willingness to pay for dengue vaccine and the revenue potential of dengue vaccine when used in various immunization strategies. • Estimate burden of illness at the national, regional and global level though development of appropriate mathematical models from various data sources; • Estimate the potential effect on disease incidence of dengue vaccination and different vaccination strategies using mathematical models. • Working with WHO and others, strengthen the quality of national, regional and international surveillance and reporting for dengue. • Monitor and manage IP related to dengue vaccines and diagnostics as appropriate. • Collaborate with manufacturers and provide assistance to developing countries with respect to regulatory affairs. • Identify and promote plans for national and international vaccine distribution in the public and private sectors; assess the potential role of manufacturers in developing countries in ensuring access by the poor; and promote creation of funding mechanisms for sustained procurement of vaccine. • Develop effective communications with health professionals, scientists, other partners and the public about dengue prevention and control, progress in dengue vaccine development, evaluation and utilization, and the PDVI.